AB | BC | MB | NB | NL | NS | NT | ON | PE | QC | SK | YT
Search National Drug Schedules Member Login

What's New

NAPRA Position Available

NAPRA is currently seeking a candidate to fill the position of Manager, Professional and Regulatory Affairs - Maternity Leave Replacement (4-5 days/week)

For a complete position description, please see the link below.

Please submit a cover letter and résumé by e-mail to KathyBedard@McConnellHRC.Com by August 10, 2016.

Manager, Professional and Regulatory Affairs - Maternity Leave Replacement (4-5 days/week)

NDSAC - Nomination sought for Committee membership

The National Drug Scheduling Advisory Committee (NDSAC) is soliciting nominations to fill a membership vacancy
[> More]

Pharmacy Technician Bridging Education Program-Course and PLAR exam schedules

Please note, this section will be updated periodically as the information becomes available.


  Reminder: Courses and PLAR exams available in both English and French

    NOTE: Selkirk College registration deadline for all English and French courses beginning in September 2016 is August 25, 2016


        Rappel :  Les cours et les examens ERA sont offerts en français et en anglais

  REMARQUE :  La date limite pour l’inscription aux cours (anglais et français) débutant en septembre 2016 au collège Selkirk est le 25 août 2016 

Registration deadlines for all institutions are available on the Course and PLAR Schedules page.

Registration for all courses is conducted directly with the educational institution offering the program.

NDSAC Meeting of September 12-13, 2016

The proposed meeting of the National Drug Scheduling Advisory Committee (NDSAC) for September 12-13, 2016 is cancelled.

The next meeting of the Committee is scheduled for December 5-6, 2016. The deadline to receive submissions for a drug scheduling application for this meeting is by end of day Thursday, October 6, 2016.

Information Update

Alere Inc. initiating voluntary withdrawal of Alere INRatio® and INRatio® 2 PT/INR Monitoring Systems that may pose serious health risks

As Health Canada previously communicated, Alere Inc. is withdrawing the Alere INRatio® and INRatio® 2 Prothrombin Time (PT) Monitoring Systems (professional use and patient self-test) devices from the Canadian market. These devices measure  blood clotting time in patients requiring warfarin and other oral blood-thinning medicines. There is a risk that the Alere devices provide an inaccurate low reading.

Health Canada Information Update


Two unauthorized products “B-Hard on Demand” and “Wonderblue” seized at  Désirs et Plaisirs in St-Jérôme, QC
may pose serious health risks

Health Canada has seized two unauthorized products being promoted as natural health products for sexual enhancement from Désirs et Plaisirs in St-Jérôme, Quebec. These products were found to contain undeclared prescription drug substances and other drug substances that may pose serious risks to the health of Canadians.

Health Canada Advisory

Health Product Risk Communication

Important Safety Information on Inferior Vena Cava (IVC) Filters and Risk of Serious Complications

Serious complications have been reported in patients implanted with an IVC filter, including caval perforation, caval thrombosis, filter fracture and fragment embolization, intracardiac migration, cardiac perforation, cardiac tamponade, and death. Many of these complications occurred with long-term (greater than 30 days) filter implantation.

Health Canada Health Product Risk Communication



Gateway for international
Portail pour pharmaciens
formés à l’étranger




National Pharmacy Technician Bridging Education Program

Students and educational institutions can find more information about NAPRA's newest program.

NDSAC Drug Scheduling Applications

Find information about the NDSAC process and how to prepare scheduling applications.